These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28440045)

  • 1. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study.
    Smith SR; Garvey WT; Greenway FL; Zhou S; Fain R; Pilson R; Fujioka K; Aronne LJ
    Obesity (Silver Spring); 2017 May; 25(5):857-865. PubMed ID: 28440045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy.
    Rebello CJ; Nikonova EV; Zhou S; Aronne LJ; Fujioka K; Garvey WT; Smith SR; Coulter AA; Greenway FL
    Obesity (Silver Spring); 2018 Feb; 26(2):332-339. PubMed ID: 29363287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM; Tungol AA; Wesolowicz LA
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
    O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
    Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
    Allison DB; Gadde KM; Garvey WT; Peterson CA; Schwiers ML; Najarian T; Tam PY; Troupin B; Day WW
    Obesity (Silver Spring); 2012 Feb; 20(2):330-42. PubMed ID: 22051941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
    Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
    Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN
    Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.
    Hollander P; Bays HE; Rosenstock J; Frustaci ME; Fung A; Vercruysse F; Erondu N
    Diabetes Care; 2017 May; 40(5):632-639. PubMed ID: 28289041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population.
    Lu CW; Chang CJ; Yang YC; Lin WY; Huang KC
    Obes Res Clin Pract; 2018 Jul; 12(5):465-471. PubMed ID: 30033356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy comparison of medications approved for chronic weight management.
    Kumar RB; Aronne LJ
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S4-7. PubMed ID: 25900871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
    Grabarczyk TR
    Pharmacotherapy; 2018 Jan; 38(1):19-28. PubMed ID: 29044720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.
    Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S
    Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes.
    Smith SR; O'Neil PM; Astrup A; Finer N; Sanchez-Kam M; Fraher K; Fain R; Shanahan WR
    Obesity (Silver Spring); 2014 Oct; 22(10):2137-46. PubMed ID: 25044799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.